Last reviewed · How we verify
DFL24498
DFL24498 is a tyrosine kinase inhibitor targeting specific oncogenic pathways in cancer cells.
At a glance
| Generic name | DFL24498 |
|---|---|
| Sponsor | Dompé Farmaceutici S.p.A |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
DFL24498 is an investigational small molecule developed by Dompé Farmaceutici for oncology indications. As a kinase inhibitor in Phase 3 development, it likely works by blocking intracellular signaling pathways that drive cancer cell proliferation and survival, though the specific molecular target has not been widely disclosed in public literature.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DFL24498 CI brief — competitive landscape report
- DFL24498 updates RSS · CI watch RSS
- Dompé Farmaceutici S.p.A portfolio CI